RxDoctor Payments DataLook up a doctor →

Justin Mansfield, MD

Internal Medicine · Ogden, UTNPI 1699707059

Payments from drug & device makers

$3,120,997in general payments, 2019–2025

Across 1,207 payments — averaging $2585.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2.1M
  • Eli Lilly$662K
  • Janssen Research & Development, LLC$132K
  • Pfizer$126K
  • Tolmar, Inc.$36K
  • Amgen$15K
  • plus $48K from 54 others
$1,458in research payments, 2019–2025

Across 2 payments — averaging $729.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$958
  • Lucid Diagnostics Inc.$500

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.58$2,101,766
Eli Lilly13$661,878
Janssen Research & Development, LLC16$131,508
Pfizer71$126,382
Tolmar, Inc.15$35,780
Amgen67$15,313
Alnylam Pharmaceuticals Inc.3$14,298
AstraZeneca14$12,963
Lumos Diagnostics, Inc.1$6,300
AbbVie(2 entities)280$4,149
Novo Nordisk146$1,421
Biohaven Pharmaceuticals, Inc.6$1,273
Astellas Pharma US Inc36$675
Novartis42$667
Lilly USA, LLC42$614
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC61$586
Nestle Healthcare Nutrition Inc.23$400
GSK25$383
Otsuka America Pharmaceutical, Inc.20$315
Axsome Therapeutics, Inc.18$300
Boehringer Ingelheim13$229
Johnson & Johnson(2 entities)13$199
Sanofi-aventis U.S. LLC14$197
Amarin Pharma, Inc.12$194
Daiichi Sankyo Inc.9$173
Takeda Pharmaceuticals U.S.A., Inc.12$170
Sumitomo Pharma America, Inc.11$168
Antares Pharma, Inc.9$154
Jazz Pharmaceuticals Inc.7$153
Lundbeck LLC7$144
Avanir Pharmaceuticals, Inc.9$130
Corium, LLC7$123
E.r. Squibb & Sons, L.L.C.8$120
Idorsia Pharmaceuticals US Inc7$112
Abbott5$93
Teva Pharmaceuticals USA, Inc.6$91
Dexcom, Inc.6$90
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$85
Boston Scientific6$80
Arbor Pharmaceuticals, Inc.5$78
Biohaven Pharmaceutical Holding Company Ltd.4$75
Biogen5$73
Halozyme Inc4$72
Merck5$63
Alkermes, Inc.4$59
Aimmune Therapeutics, Inc.3$59
Sunovion Pharmaceuticals Inc.5$59
Exact Sciences3$58
Bausch Health US, LLC4$55
Lucid Diagnostics Inc.3$43
Lifescan, Inc.2$41
Scilex Pharmaceuticals Inc.3$39
Stryker1$37
Redhill Biopharma Inc.2$34
Phathom Pharmaceuticals, Inc.2$33
Harmony Biosciences LLC2$29
Medtronic2$29
Esperion Therapeutics, Inc.2$29
Corcept Therapeutics2$28
Acadia Pharmaceuticals Inc2$26

How this compares

$3,120,997 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$532,585
Medicare patients
906
Services billed
42,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →